These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22672985)

  • 1. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
    Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
    Lee S; Yoon S; Kim DH
    Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
    Kawaguchi W; Itamochi H; Kigawa J; Kanamori Y; Oishi T; Shimada M; Sato S; Shimogai R; Sato S; Terakawa N
    Cancer Sci; 2007 Dec; 98(12):2002-8. PubMed ID: 17900261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
    Champelovier P; El Atifi M; Pautre V; Rostaing B; Berger F; Seigneurin D
    Exp Hematol; 2008 Jan; 36(1):28-36. PubMed ID: 17949889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
    Coltella N; Rasola A; Nano E; Bardella C; Fassetta M; Filigheddu N; Graziani A; Comoglio PM; Di Renzo MF
    Int J Cancer; 2006 Jun; 118(12):2981-90. PubMed ID: 16395709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
    Wang LJ; Wang SG; Deng TX
    Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
    Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
    Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.